Research programme: sepsis preventative therapy - Diomune
Latest Information Update: 11 Aug 2016
At a glance
- Originator Diomune
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Sepsis
Most Recent Events
- 11 Aug 2016 Sepsis preventative therapy - Diomune receives Orphan Drug status for Sepsis (In neonates, Prevention) in European Union
- 11 Aug 2016 Early research in Sepsis (In neonates, Prevention) in Spain (unspecified route)